[go: up one dir, main page]

WO2008112290A3 - Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer - Google Patents

Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer Download PDF

Info

Publication number
WO2008112290A3
WO2008112290A3 PCT/US2008/003355 US2008003355W WO2008112290A3 WO 2008112290 A3 WO2008112290 A3 WO 2008112290A3 US 2008003355 W US2008003355 W US 2008003355W WO 2008112290 A3 WO2008112290 A3 WO 2008112290A3
Authority
WO
WIPO (PCT)
Prior art keywords
ovarian cancer
ephb4
therapeutic target
diagnostic marker
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/003355
Other languages
French (fr)
Other versions
WO2008112290A2 (en
Inventor
Valery Krasnoperov
Parkash Gill
Anil K Sood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MD Anderson Cancer Center
Vasgene Therapeutics Inc
Original Assignee
MD Anderson Cancer Center
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MD Anderson Cancer Center, Vasgene Therapeutics Inc filed Critical MD Anderson Cancer Center
Priority to EP08726797A priority Critical patent/EP2137216A2/en
Priority to CA2703136A priority patent/CA2703136A1/en
Priority to CN2008800150976A priority patent/CN101932604A/en
Priority to JP2009553630A priority patent/JP2010521467A/en
Priority to AU2008226824A priority patent/AU2008226824A1/en
Publication of WO2008112290A2 publication Critical patent/WO2008112290A2/en
Publication of WO2008112290A3 publication Critical patent/WO2008112290A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57545—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

In certain embodiments, this present invention provides compositions, and methods for inhibiting EphB4 activity in ovarian cancer. In other embodiments, the present invention provides methods and compositions for treating ovarian cancer.
PCT/US2008/003355 2007-03-12 2008-03-12 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer Ceased WO2008112290A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP08726797A EP2137216A2 (en) 2007-03-12 2008-03-12 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
CA2703136A CA2703136A1 (en) 2007-03-12 2008-03-12 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
CN2008800150976A CN101932604A (en) 2007-03-12 2008-03-12 Use of EphB4 as a diagnostic marker and as a therapeutic target for ovarian cancer
JP2009553630A JP2010521467A (en) 2007-03-12 2008-03-12 Use of EphB4 as a diagnostic marker and therapeutic agent targeting ovarian cancer
AU2008226824A AU2008226824A1 (en) 2007-03-12 2008-03-12 Use of EphB4 as a diagnostic marker and a therapeutic target for ovarian cancer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90672707P 2007-03-12 2007-03-12
US90676407P 2007-03-12 2007-03-12
US60/906,727 2007-03-12
US60/906,764 2007-03-12

Publications (2)

Publication Number Publication Date
WO2008112290A2 WO2008112290A2 (en) 2008-09-18
WO2008112290A3 true WO2008112290A3 (en) 2008-12-31

Family

ID=39684343

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003355 Ceased WO2008112290A2 (en) 2007-03-12 2008-03-12 Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer

Country Status (6)

Country Link
EP (1) EP2137216A2 (en)
JP (1) JP2010521467A (en)
CN (1) CN101932604A (en)
AU (1) AU2008226824A1 (en)
CA (1) CA2703136A1 (en)
WO (1) WO2008112290A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156642A1 (en) * 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
BRPI0815399A2 (en) 2007-08-13 2019-09-24 Vasgene Therapeutics Inc cancer treatment using humanized antibodies that bind ephb4
US8357501B2 (en) * 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
JP2010204086A (en) * 2009-02-09 2010-09-16 Nippon Koden Corp Method of producing cellularization treatment liquid, method of measuring amount of dna in cell nucleus, and kit used for the same
DK2668210T3 (en) 2011-01-26 2020-08-24 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND USES THEREOF
WO2014018625A1 (en) 2012-07-25 2014-01-30 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN113975386A (en) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 Treatment of eosinophil or mast cell related disorders
BR112017002888A2 (en) 2014-08-12 2017-12-05 Nextgen Jane Inc system and method for health monitoring in body fluid collected
EP3442706B1 (en) 2016-04-13 2025-07-23 NextGen Jane, Inc. Sample collection and preservation methods
AU2020241963A1 (en) * 2019-03-17 2021-11-04 Vasgene Therapeutics Inc Treatment of cancers using sEphB4-HSA fusion proteins
AU2022343102A1 (en) * 2021-09-07 2024-03-21 Vasgene Therapeutics Inc. Diagnostic methods for cancer using ephrinb2 expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024773A1 (en) * 2002-09-16 2004-03-25 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
EP1508337A2 (en) * 1998-11-20 2005-02-23 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2007130697A2 (en) * 2006-01-05 2007-11-15 Genentech, Inc. Anti-ephb4 antibodies and methods using same
WO2008042941A2 (en) * 2006-10-04 2008-04-10 Medimmune, Llc Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1508337A2 (en) * 1998-11-20 2005-02-23 Genentech, Inc. Uses for eph receptor antagonists and agonists to treat vascular disorders
WO2004024773A1 (en) * 2002-09-16 2004-03-25 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
WO2007130697A2 (en) * 2006-01-05 2007-11-15 Genentech, Inc. Anti-ephb4 antibodies and methods using same
WO2008042941A2 (en) * 2006-10-04 2008-04-10 Medimmune, Llc Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CASTELLANO GIANCARLO ET AL: "New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, vol. 66, no. 22, 15 November 2006 (2006-11-15), pages 10709 - 10719, XP009104757, ISSN: 0008-5472 *
DAMSCHRODER ET AL: "Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 44, no. 11, 22 January 2007 (2007-01-22), pages 3049 - 3060, XP005938388, ISSN: 0161-5890 *
DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933 *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
KUMAR S R ET AL: "The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 96, no. 7, 10 April 2007 (2007-04-10), pages 1083 - 1091, XP009104758, ISSN: 0007-0920 *
LITTLE M ET AL: "Of mice and men: hybridoma and recombinant antibodies", IMMUNOLOGY TODAY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 8, 1 August 2000 (2000-08-01), pages 364 - 370, XP004215163, ISSN: 0167-5699 *
NAKAMOTO MASARU ET AL: "Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis", MICROSCOPY RESEARCH AND TECHNIQUE, WILEY-LISS, CHICHESTER, GB, vol. 59, no. 1, 1 October 2002 (2002-10-01), pages 58 - 67, XP002464008, ISSN: 1059-910X *
WU ET AL: "The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 102, no. 1, 1 July 2006 (2006-07-01), pages 15 - 21, XP005485643, ISSN: 0090-8258 *

Also Published As

Publication number Publication date
JP2010521467A (en) 2010-06-24
CN101932604A (en) 2010-12-29
EP2137216A2 (en) 2009-12-30
CA2703136A1 (en) 2008-09-18
WO2008112290A2 (en) 2008-09-18
AU2008226824A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2008089397A3 (en) Adrb2 cancer markers
WO2008030883A3 (en) Treatment of cancer
WO2008046911A3 (en) Novel human micrornas associated with cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
WO2007011962A3 (en) Treatment of cancer
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2009006577A3 (en) Compositions and methods for inhibiting ezh2
WO2008146911A1 (en) Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody
WO2007053573A3 (en) Treatment of cancer with sorafenib
EP2592156A3 (en) Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009108860A8 (en) Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders
WO2008120098A3 (en) Peptide prodrugs
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2008060945A3 (en) Diagnosis and treatment of breast cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880015097.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08726797

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009553630

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008226824

Country of ref document: AU

Ref document number: 2008726797

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008226824

Country of ref document: AU

Date of ref document: 20080312

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2703136

Country of ref document: CA